Diuretic Therapy

Mechanism and Risk Factors

• Thiazide and loop diuretics, such as metolazone, bumetanide, and torsemide, can cause hypokalemia and potentially hyponatremia, as noted by the American Heart Association and the American Thoracic Society 1, 2
• Furosemide inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, leading to hypokalemia and potentially hyponatremia 2

Patient-Specific Risk Factors

• Liver disease, especially cirrhosis, increases the risk of hyponatremia, according to the American Association for the Study of Liver Diseases 3
• Elderly patients are at higher risk of hyponatremia when taking diuretics, as recommended by the Annual Review of Nutrition 4

Prevention and Management

• Combining thiazide or loop diuretics with potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene) can prevent hypokalemia, as suggested by the American College of Physicians, the American Thoracic Society, and the International Society of Nephrology 2, 5
• Chlorthalidone is a thiazide-like diuretic used in hypertension and edema management, with a longer duration of action compared to hydrochlorothiazide, as recommended by the American College of Cardiology, American Heart Association, European Society of Cardiology, and European Society of Hypertension 6, 7, 8, 9
• The following table compares the risk of hypokalemia and duration of action of Chlorthalidone and Hydrochlorothiazide:

• Regular monitoring of serum sodium is essential in high-risk patients taking high-risk medications, with checks recommended within 1-2 weeks of starting hydrochlorothiazide or venlafaxine, especially in elderly females 6, 10
• Patients should be educated about early symptoms of hyponatremia, including headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, and severe symptoms such as hallucination, syncope, seizure, and coma 11
• For patients with hyponatremia, the following management strategies are recommended:

Combination Therapy

• Chlorthalidone can be effectively combined with Telmisartan (ARB) or Amlodipine (CCB) for blood pressure control, as recommended by the American College of Cardiology 12
• Combining Chlorthalidone with Metoprolol (Beta-blocker) requires monitoring for hypotension 12
• ACE inhibitors or ARBs are effective alternatives to chlorthalidone, particularly in patients with diabetes or albuminuria, according to the American College of Cardiology 10
• Calcium channel blockers can be considered as first-line alternatives to chlorthalidone, as recommended by the American College of Cardiology 10
• Beta blockers are recommended as preferred agents for patients with thoracic aortic disease, as suggested by the American Heart Association 6

Special Considerations

• Chlorthalidone remains effective even in patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²), contrary to common misconceptions 13
• Diuretics should not automatically be discontinued when eGFR decreases below 30 mL/min/1.73 m², as suggested by the American Journal of Kidney Diseases 13
• Close monitoring of electrolytes, renal function, and blood pressure is essential when adding Chlorthalidone to the current medication regimen 12
• Chlorthalidone may affect glucose metabolism, and therefore requires monitoring in diabetic patients, as recommended by the American Heart Association 1